IEO is one of the world's most prestigious hospitals and the fastest growing comprehensive cancer centre in Europe. IEO integrates the various area related to the fight against cancer such as prevention, diagnosis, treatment, training and education, basic and translational research.
At IEO, we work to transform scientific research to new treatments in real time. We aim to achieve this through clinical and scientific research development, organisational and management innovation, with a constant focus on the quality of the service provided to the patients.
NovaRNA is an innovative mRNA platform with preclinical validation. It addresses key limitations of existing mRNA therapeutics by enhancing antigen expression and immune response through proprietary engineering of untranslated regions.
Pre-seed funding | Idea validation
Seed funding | Get business started
Author
IP & Technology Transfer Specialist at Istituto Europeo di Oncologia (IEO)
Novel Flagellin-related peptides that stimulate antitumor immune responses, validated in human samples and in vivo melanoma models, with the potential to enhance the effectiveness of immunotherapies.
Pre-seed funding | Idea validation
Seed funding | Get business started
Author
IP & Technology Transfer Specialist at Istituto Europeo di Oncologia (IEO)
iRASP is an in vivo antibody discovery platform that identifies novel tumor-specific antibodies without prior knowledge of the target antigen, enabling the development of new cancer immunotherapies.
Pre-seed funding | Idea validation
Seed funding | Get business started
Author
IP & Technology Transfer Specialist at Istituto Europeo di Oncologia (IEO)
Innovative multigene signature designed to identify NMIBC patients at high-risk of progression and recurrence, providing a powerful tool for precise clinical decision-making.
Pre-seed funding | Idea validation
Seed funding | Get business started
Author
IP & Technology Transfer Specialist at Istituto Europeo di Oncologia (IEO)